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Abstract
Background: We have studied the possible effects of an intensive lifestyle change program on plasma fibrinogen
levels, in patients with no cardiovascular disease, with elevated levels of fibrinogen, normal cholesterol levels, and a
moderate estimated risk of coronary heart disease (CHD) and we have also analysed whether the effect on
fibrinogen is independent of the effect on lipids.
Results: This clinical trial was controlled, unblinded and randomized, with parallel groups, done in 13 Basic Health
Areas (BHA) in l’Hospitalet de Llobregat (Barcelona) and Barcelona city. The study included 436 patients, aged between
35 and 75 years, with no cardiovascular disease, elevated levels of fibrinogen (> 300 mg/dl), cholesterol < 250 mg/dl,
218 of whom received a more intensive intervention consisting of advice on lifestyle and treatment. The follow-up
frequency of the intervention group was every 2 months. The other 218 patients followed their standard care in the
BHAs. Fibrinogen, plasma cholesterol and other clinical biochemistry parameters were assessed.
The evaluation of the baseline characteristics of the patients showed that both groups were homogenous. Obesity
and hypertension were the most prevalent risk factors. After 24 months of the study, statistically significant
changes were seen between the adjusted means of the two groups, for the following parameters: fibrinogen,
plasma cholesterol, systolic and diastolic blood pressure and body mass index.
Conclusion: Intensive intervention to achieve lifestyle changes has shown to be effective in reducing some of the
estimated CHD factors. However, the effect of intensive intervention on plasma fibrinogen levels did not correlate
with the variations in cholesterol.
Trial Registration: ClinicalTrials.gov: NCT01089530
Keywords: Fibrinogen, Cholesterol, Cardiovascular risk factors, Primary prevention
Background
This manuscript is a translation of our already published
manuscript [1]. Fibrinogen can be considered an inde-
pendent cardiovascular risk factor (CVRF) [2,3]. How-
ever, several studies have shown a correlation between
cholesterol (CT) and fibrinogen levels [4]. Also it has
been argued that the elevated levels of fibrinogen may
be influenced by environmental factors, diet, smoking,
excess weight and physical exercise [5]. Various clinical
and epidemiological studies have described the implica-
tions of the elevated plasma fibrinogen values as CVRF
in coronary, cerebral disease and peripheral arteries.
The Northwick Park Heart study describes a relation-
ship between high values of plasma fibrinogen and the
risk of coronary ischemia [6]. In REGICOR study [7], it
was described as an average of fibrinogen of 2.92 g/l in
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fibrinogen being highest in the subset of smoking
patients. The study published by Gil et al. [8], described
an intervention study done in a primary care setting, in
patients with an average age of 72.6 years and with sev-
eral CVRF; the prevalence of hyperfibrinogenemia was
found to be 26.5%. Other studies in younger patients
with an average age of 57 and clinical manifestations of
cardiovascular disease, have found a prevalence of 60%
[9,10]. In different epidemiological studies, such as the
Yano et al. [11], an increase in cardiovascular morbidity
and mortality has been shown in patients with fibrino-
gen levels above 300 mg/dl.
Lifestyle interventions make a notable impact on some
of the modifiable CVRF; in spite of this, there are not
many studies who have analysed the effects of these
modifications (smoking cessation, diet and physical
exercise) on fibrinogen levels. In addition, these studies
have been conducted in settings different from ours,
and mostly at short term [5,6]. Because of this, we have
designed a study of intervention, in the primary care
setting, to assess the effect on the fibrinogen levels in a
subset of patients with intensive intervention (in fre-
quency and intensity) on changes in their lifestyle, as
compared to a control group, according to the usual
intervention practiced in the basic areas of health
(BHA). The study has been done in patients with fibri-
nogen levels > 300 mg/dl, total cholesterol < 250 mg/dl
and an estimated moderate or high CHD risk according
to Framingham [12], adjusted according to fibrinogen
levels [12,13] and had a follow up period of 2 years on
each subject.
Aims
Primary aim To evaluate the effect of an intensive inter-
vention to modify lifestyle (hypo caloric diet, smoking
cessation and physical exercise) in the fibrinogen levels
in patients without cardiovascular disease with hyperfi-
brinogenemia (> 300 mg/dl), total cholesterol levels less
than 250 mg/dl and an estimated moderate or high
CHD risk.
Secondary aim
(a) To assess the effect of this intensive intervention in
some of the modifiable Cardiovascular Risk Factors.
(b) To confirm that this effect is independent of the
variations of the total cholesterol levels.
Methods
We designed a randomized, controlled clinical trial, par-
allel groups, consisting of 436 patients, divided into two
groups: a) an intensive intervention group, both in the
frequency and intensity of their changes in lifestyle, b) a
control group, receiving the standard therapy. The
protocol has been described in a previous publication
[14]. The study was approved by Jordi Gol I Gurina
EECC.
Inclusion criteria
- Patients of both genders, aged between 30 and 75
years, in which in two consecutive analyses, separated
by a minimum interval of 15 days, with fibrinogen levels
> 300 mg/dl and plasma total cholesterol < 250 mg/dl.
- Agreement to participate in the study, with written
informed consent using procedures reviewed and
approved by the EECC review board.
Exclusion criteria
- Any lipid-lowering therapy (dietary or pharmacologi-
cal intervention).
- Local or generalized infection, either acute or
chronic.
- History of cardiovascular disease, according to medi-
cal records and/or anamnesis.
- Fibrinogen lowering therapies (ticlopidine, fibrates,
pentoxifylline)
- Severe clinical pathology (terminally ill patients,
dementia, etc.)
Sample size calculation
We have assumed that:
1. The prevalence of smoking, overweight, obesity and
sedentarism in the study population are 28, 48 and 84%
[7], respectively.
2. The effectiveness of common interventions are:
[5,13]
- Giving Up Smoking Advice: 38%.
- Dietary recommendations for overweight/obese
patients: 20%.
- Increase physical activity recommendations in
sedentary patients: 30%.
3. Smoking cessation and regular physical activity
(measured by means of one unit of sporting activity)
reduces, on average, fibrinogen levels by 0.4 g/l, and a
diet of 1,000-1,400 cal/day reduces mean fibrinogen
from 3 to 2.8 g/l [5], during a complete follow up of
one year.
Taking into account the prevalence of the cardiovas-
cular risk factors described, the effectiveness of these
interventions, its impact on fibrinogen levels and assum-
ing an additive effect of all of them, we aim to achieve a
mean reduction of fibrinogen of 17. 2 mg/dl, after a
complete follow up of one year.
4. Intensive intervention will get an average reduction of
fibrinogen levels twice as much as the standard one, i.e. a
reduction of 34.4 mg/dl, during a follow up of one year.
5. An alpha risk of 5%, 80% (1-beta) power and that
the standard deviation of fibrinogen is 55 mg/dl [5].
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Considering all these assumptions, the study was
planned to include more than 436 patients.
Randomisation
Patients meeting the inclusion and exclusion criteria
listed above were selected consecutively from those vis-
ited by the participating investigators.
Random allocation sequence
A blocked random allocation sequence was centrally
generated by an statistician.
Blocks contained six participants, so that three of
them will receive the usual intervention and three the
intensive intervention. The order of assigned interven-
tions within each block was randomised. When a
investigator received the informed consent of a
patient, he phoned a member of the research team,
w h oa s s i g n e dp a r t i c i p a n t st ot h ec o r r e s p o n d i n g
intervention.
Description of the groups
Control group. This subset of patients have received
advice about their lifestyle (diet, exercise and smoking
cessation) according to the practice guidelines of the
‘Institut Català de la Salut’(ICS), following nernational
consensus [12,15].
Intervention group. An active follow up of this group
of patients was done, consisting of:
- Phone calls to get psychologist support, and letters
to record each visit with the physician, additional mea-
sures to encourage the maintenance of lifestyle modifi-
cations, which will be done every 2 months. In each
visit, physical activity questionnaires were done, as well
as both pharmacological medical recommendations and
lifestyle changes [15-17]. A laboratory analysis was done
every 8 months (Table 1).
Blinding
Due to the nature of the study, patients and physicians
allocated to the intervention group were aware of the
allocated arm. However, outcome assessors and data
analysts were kept blinded to the allocation.
Definitions and methods of measurement of outcome
variables:
Administrative data: complete name, address and tel-
ephone number, name of the medical center of pri-
mary care, medical history, number of medical
record, date of registration, date of birth and sex.
Toxic history: smoking habits (daily consumption of
tobacco in number of cigarettes), alcohol consump-
tion (g/day).
Pathological history: Arterial hypertension (HBP),
diabetes mellitus (DM), dislipaemia, overweight/obe-
sity, chronic obstructive pulmonary disease.
Physical examination: weight (kg), size (cm), Body
Mass Index (BMI) (kg/m2), Systolic Blood Pressure
(SBP) and Diastolic Blood Pressure (DBP).
Physical activity: classification of the patient, accord-
ing to the intensity of their physical activity: active,
partially active or inactive.
Analytical data: Fibrinogen, Total cholesterol, High
density lipoprotein cholesterol (HDL-C) Low density
lipoprotein cholesterol (LDL-C), triglycerides, glu-
cose, uric acid, Hematocrit (%), white blood cells
and platelets.
Collection data and analysis: design of a data collec-
tion form, on which is listed data identification, vari-
ables of the study and the frequency of visits.
All patients provided written informed consent.
Statistical analysis
The initial characteristics of both groups have been
compared by means of bivariate techniques: c 2t e s t ,i n
the case of proportions, and t Student test, in case of
means. Analysis of Covariance was used to calculate the
effect of the kind of intervention the final fibrinogen
adjusted to the total cholesterol values.
To analyze the possible association between the type
of intervention (dichotomous qualitative variable) and
response variable (plasmatic fibrinogen levels, quantita-
tive variable), Covariance analysis (ANCOVA) will be
used. This statistical technique allows us to obtain 2
regression lines, parallel, that correlates the results of
fibrinogen levels post intervention with the individual
baseline, in each group of intervention, without a possi-
ble influence of the fibrinogen level values pre or post
intervention between the 2 groups. This technique is
also used to verify that the effect of the intervention in
the final fibrinogen levels is independent of the final
total cholesterol variations.
Results
39 of the 624 patients at baseline decided not to partici-
pate, 19 were excluded because they did not meet inclu-
sion criteria and 130 have an inappropriate laboratory
analysis.
Of the remaining patients that met inclusion criteria,
438 were randomized and assigned to one of the 2
groups, and followed for a 2 year period. At the end of
the 2 years, 72 were lost in the intensive intervention
group, 64 in the standard intervention group, (Figure 1).
The percentage of patients lost in the follow up was
similar for the 2 groups.
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the population assigned to each group. Both groups
were homogenous, with neither statistically significant
nor clinically relevant differences between them. The
percentage of individuals who smoked was somewhat
higher in the Group of intensive intervention (31.9%) as
compared to the standard group (26.8%), while in this
last group the number of diabetic patients is slightly lar-
ger (15.1% versus 11.9%).
Regarding the presence of cardiovascular risk factors,
the prevalence of obesity and hypertension were, respec-
tively, 55.5 and 41.4% in the standard group, and 46.8
and 42.7% in the intensive intervention group.
Table 3 shows the results of the analysis per protocol
of the main outcomes of the study, according to the
type of intervention, after a 2 year follow-up. When ana-
lyzing fibrinogen levels, we could find a difference 31.0
mg/dl between the mean adjusted fibrinogen levels,
showing a statistically significant (p < 0.001) difference
in favour of the intensive intervention. We could also
see statistically significant differences in favour of
Table 1 Treatment of patients with intensive intervention
Definition Objectives Intervention Periodicity
Smoking People who has
smoked daily, any
amount of cigarettes,
over the last month.
Smoking
cessation
Smoking history
Degree of dependency
Motivation to give up smoking
Clear and tailored
advice
A follow-up program
for those patients who
stop smoking
Use of TSN or
bupropion
2 months
Physical
activity
Among the activities
that people do over a
24 h period,
occupational related
practices, leisure and
free time are the
most important ones.
Increase the
physical
activity
Interview about
physical activities and
classify: active,
partially active or
sedentary.
2 months
Advice to start,
increase or sustain
physical activities.
Obesity,
overweight
Body mass index
(BMI) BMI > 30
kg/m
2 = obesity 25-
30 kg/m
2 =
overweight
IMC 20-25
kg/m
2
Gradual weight loss
0.51 kg per week
Advice healthy diet
once objectives are
achieved
2 months
Hypertension SBP ≥ 140 mmHg
and/or DBP ≥ 90
mmHg
PA < 140/90
mmHg
Diabetics BP <
130/80 mmHg
Dietary measures or
pharmacological
treatment, according to
guidelines
2 months
Diabetes
mellitus
Two basal glycemias
in venous serum ≥
126 mg/dl
HbA1C < 7% Dietary measures or
pharmacological
treatment according to
guidelines
2 months
HbA1C glycated hemoglobin, BP blood pressure; SBP BP systolic diastolic; SBP diastolic blood pressure; TSN replacement therapy with nicotine
Figure 1 General outline of the study.
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cholesterol, SBP, DBP and BMI.
Table 4 shows the result of the ‘per protocol evalua-
tion’ of ‘tobacco consumption’ variable according to the
type of intervention. The difference in the proportion of
smokers at the end the study is statistically significant as
compared to the initial for each type of intervention,
although we didn’t find any significant differences
between the proportions of smokers in groups at the
end of the study.
Figure 2 shows the relationship between the fibrino-
gen levels and total cholesterol at the end of the study,
according to type of intervention. The Covariance analy-
sis done has not shown any statistically significant rela-
tionship between the fibrinogen levels and the total
cholesterol at the end of the study.
Discussion
Baseline demographics did not differ significantly
between the 2 groups (Table 2).
The prevalence of some of the cardiovascular risk fac-
tors, such as hypertension, diabetes mellitus and smok-
ing are similar to other population studies carried out in
our environment [15,18]. However, obesity, in our study,
has shown a higher prevalence, possibly due to the char-
acteristics of the population included: patients who vis-
ited their physician, mean average age of 57 years, and
an estimated moderate or high cardiovascular risk, dif-
ferent from the usual care setting. These results con-
firms what other investigators have found in relation to
obesity [19,20], that it is becoming a major health pro-
blem, and desirable implement innovative strategies to
prevent and treat it are urgently need.
The lifestyle modification- intensive intervention
group, at the end of a 2 years of follow-up period,
showed a significant reduction of the weight and BMI,
as compared to the standard intervention group.
The results of our patients confirm data from other
studies [20,21], showing that lifestyle changes are effec-
tive in patients with overweight and obesity.
After 24 months of follow-up, we found a reduction sta-
tistically significant of total cholesterol, fibrinogen levels,
SBP, DBP and BMI in the intensive intervention group,
and showing no differences in other analyzed variables.
These results are similar to the ones found in a study
done in 20 centers in a primary care setting in United
Kingdom [21], which assessed the effectiveness of the
motivational interview to modify the intake of fat, physi-
cal activity, SBP and DBP, as well as tobacco consump-
tion in 883 patients with risk high cardiovascular
disease. It was obtained a benefit in the intervention
group, but these changes could not be neither controlled
nor related to the changes achieved in fibrinogen levels.
It is well known that one of the tables used to calcu-
late the estimated cardiovascular risk in primary preven-
tion are tables of Framingham [22,23]. Some authors
[13] have proposed to adjust the obtained risk according
to fibrinogen levels.
In our study, the fibrinogen levels values in the inten-
sive- intervention group were decreased an average of
31 mg/dl. This would mean that, in the case of a male
patient with a 330 mg/dl fibrinogen level, considered an
estimated high risk calculated by adjusted Framingham
tables by the plasma figures and received intensive inter-
vention, could move to a moderate risk and, therefore,
change the therapeutic goal.
Conclusions
In our study, intensive intervention of lifestyle modifica-
tions have been shown effective to reduce some major
Table 2 Baseline characteristics of participants
depending on the type intervention assigned*
Standard
intervention
(n = 154)
Intensive
intervention
(n = 146)
Women, n (%) 98(63.6) 92(63.0)
Men, n(%) 56(36.4) 54(37.0)
Age in years 58.6 ± 10.6 56.8 ± 10.6
Fibrinogen, mg/dl 368.7 ± 64.5 364.9 ± 59.4
Total cholesterol, mg/dl 210.2 ± 25.5 211.1 ± 26.7
Tryglicerides, mg/dl 116.6 ± 59.6 116.5 ± 54.3
cHDL, mg/dl 55.2 ± 13.1 54.2 ± 12.0
cLDL, mg/dl 134.3 ± 28.6 134.6 ± 26.9
Basal glucose, mg/dl 108.3 ± 33.1 108.5 ± 35.9
Hematocrit,% 42.0 ± 3.7 42.1 ± 3.4
Leucocytes, 10e
12/l 7.6 ± 3.0 7.4 ± 2.0
Platelets, 10e
9/l 243.0 ± 60.2 252.3 ± 67.6
Weight, kg 76.7 ± 12.9 75.7 ± 13.1
Height, cm 158.7 ± 8.4 158.7 ± 9.8
SBP, mmHg 134.7 ± 18.0 133.8 ± 17.4
DBP, mmHg 81.7 ± 9.4 80.7 ± 9.8
BMI, kg/m
2 30.5 ± 5.1 30.3 ± 5.8
Obesity, (%) (55.5%) (46.8%)
Tobacco, (%) (26.8%) (31.9%)
Hipertensión arterial(%) (41.4%) (42.7%)
Diabetes mellitus(%) (15.1%) (11.9%)
HbA1c% in diabetic
patients
6.9 ± (1.7) 7.1 ± (1.5)
*The values represent mean ± standard deviation, except those in bold,
representing number of patients (percentage)
cHDL high density lipoprotein cholesterol,
cLDL low density lipoprotein cholesterol;
SBP systolic blood pressure;
DBP diastolic blood pressure;
BMI body mass index;
HbA1C glycated haemoglobin
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DBP and BMI. The effect of the intensive intervention
in the fibrinogen plasma values is not correlated with
variations the total cholesterol.
Lifestyle modification might play a role in reducing
future cardiovascular events in healthy subjects with
hyperfibrinogenemia.
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Table 4 Results of the per protocol analysis after two years of follow-up according to type of intervention for the
variable ‘tobacco consumption’
Proportion of smokers Intensive intervention Standard intervention Difference of proportions p value
a
Before 31.9% 26.8% 5.1% 0.372
After 19.4% 22.1% 2.7% 0.669
Before-after difference 12.5% 4.7%
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2 (comparison of proportions in independent groups)
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